Where Immunology Meets Topical Innovation

Built on more than 25 years of immunological research, Mallia brings a new perspective to hair thinning—focused on the biology of the scalp, not just surface-level solutions.
  • Where Immunology Meets Topical Innovation

    Built on more than 25 years of immunological research, Mallia brings a new perspective to hair thinning—focused on the biology of the scalp, not just surface-level solutions.

  • Our Origin

    Our Origin From CD83 Research to Topical Application


    Mallia Therapeutics was founded by leading European researchers specializing in immune modulation, CD83 biology, and translational immunology.

    Among them is Prof. Dr. Alexander Steinkasserer, Head of Immune Modulation at University Hospital Erlangen in Germany and a leading authority in CD83 research.

    His work has helped advance the understanding of soluble CD83 (sCD83)—a naturally occurring protein studied for its role in immune regulation and regenerative processes.

    That research now serves as the foundation for Mallia’s work, bridging scientific discovery with practical, real-world application.

  • Our Approach

    From Immunology Research to Topical Application

    Mallia operates across both pharmaceutical and cosmetic development pathways, translating the same underlying research across different regulatory settings.

    While pharmaceutical development continues in Europe, the U.S. formulation is positioned as a topical cosmetic—designed for localized scalp application.

    This dual-pathway model reflects a disciplined approach to innovation, grounded in science while aligned with real-world use.

  • In practice, this means:

    • Grounding development in peer-reviewed research
    • Aligning formulations with market-specific regulatory frameworks
    • Communicating clearly with both physicians and patients
    • Collaborating with dermatology and aesthetic professionals
  • Our Perspective

    Substance Over Trends

    Mallia is not a traditional cosmetics company.

    Its work begins with a scientific question: what biological factors influence hair growth beyond genetics?

    For more than 25 years, research into these underlying mechanisms has shaped the company’s direction.

    Ultimately, our goal is simple: to develop products grounded in evidence and designed for consistent, simple use.



    This foundation informs the development of 8T3 Essentials Hair Serum—a topical approach designed to support the scalp environment where hair thinning begins.

  • ABOUT DR. ALEXANDER STEINKASSERER

    Dr. Alexander Steinkasserer is a German-Italian immunologist whose early academic work includes serving as a research fellow at the University of Oxford’s Department of Biochemistry and MRC Immunochemistry Unit under Robert B. Sim from 1989 to 1993. He later held leadership roles in industry, including Laboratory Head at the Novartis Research Institute, before going on to become Professor of Immune Modulation at the University Hospital Erlangen at the Friedrich-Alexander University Erlangen–Nuremberg (FAU). These academic and industry experiences helped shape his long-standing focus on the biology of dendritic cells and the CD83 molecule.

    Over the course of his academic career, Dr. Steinkasserer has authored more than 170 peer-reviewed publications and contributed to foundational research on the membrane-bound CD83 (mCD83) and soluble form of CD83 (sCD83), helping to establish their relevance across immunology and translational science. These academic and industry experiences have shaped his long-standing focus on the biology of dendritic cells and the CD83 molecule.

    Dr. Steinkasserer’s research has consistently centered on how the body maintains balance within the immune system, particularly in conditions where that immune balance is disrupted, e.g. due to inflammation. His group was among the first to identify and characterize soluble CD83, and to explore its broader biological implications in areas such as autoimmune conditions and transplantation. This work has been supported by both academic institutions and industry collaborations, reflecting a long-standing focus on translating laboratory findings into practical applications.

    The connection to hair follicle biology emerged later in this research trajectory. After more than 20 years of studying the CD83 molecules in immunological contexts, an unexpected observation during preclinical work on wound repair revealed changes in the local tissue environment, and even more interesting, the presence of increased and newly formed hair follicles. This finding prompted a deeper investigation into how the same underlying biology might relate to the scalp and hair growth, extending the scope of sCD83 research into a new domain.

  • Dr. Steinkasserer is a co-founder of Mallia Innovations, where this body of research is being further developed across both pharmaceutical and topical applications. His role reflects a broader commitment to translational science, advancing research from the laboratory into formats that can be studied, evaluated, and ultimately evaluated and implemented in applied human settings.